Patents Assigned to Sunovion Pharmaceuticals Inc.
  • METHODS AND COMPOSITIONS OF DASOTRALINE FOR TREATMENT OF ADHD
    Publication number: 20170266133
    Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.
    Type: Application
    Filed: May 12, 2015
    Publication date: September 21, 2017
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Antony D. LOEBEL, Kenneth S. KOBLAN
  • Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders
    Patent number: 9758529
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: September 12, 2017
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Milan Chytil, Sharon Engel, Taleen G. Hanania, Vadim Alexandrov, Emer Leahy
  • Metabotrophic glutamate receptor 5 modulators and methods of use thereof
    Patent number: 9708331
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: July 18, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE
    Publication number: 20170157067
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Application
    Filed: October 20, 2016
    Publication date: June 8, 2017
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Thomas JERUSSI, Qun Kevin FANG, Mark G. CURRIE
  • Sublingual apomorphine
    Patent number: 9669020
    Abstract: The invention features mucoadhesive sublingual films containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine. The pH neutralizing agent in these films can be sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic, or a mixture thereof.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Sublingual apomorphine
    Patent number: 9669021
    Abstract: Disclosed are methods of treating Parkinson's disease by (i) providing a pharmaceutical composition in unit dosage form that is a film having a first portion including apomorphine particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent, where the film contains the acid addition salt of apomorphine in an amount effective to treat Parkinson's disease, and (ii) administering the film by placing the film sublingually in the mouth of the subject and contacting sublingual mucosal tissue with the film.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Sublingual apomorphine
    Patent number: 9669019
    Abstract: Disclosed are sublingual formulations of apomorphine in unit dosage form formulated for sublingual administration, where the unit dosage form is a mucoadhesive film containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine, and where the mucoadhesive film is formed by the steps of: (i) combining a film-forming mucoadhesive polymer, apomorphine particles comprising an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form a first film comprising the apomorphine particles, where the steps further include contacting or impregnating the first film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Heteroaryl compounds and methods of use thereof
    Patent number: 9670230
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Philip Jones
  • Sublingual apomorphine
    Patent number: 9669018
    Abstract: Disclosed are methods of preparing a pharmaceutical composition that is a mucoadhesive film by: (i) combining a film-forming mucoadhesive polymer, apomorphine particles containing an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form an intermediate film including the apomorphine particles; where the method further includes contacting or impregnating the intermediate film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
    Patent number: 9586888
    Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: March 7, 2017
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
  • Modulators of opioid receptors and methods of use thereof
    Patent number: 9580409
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as pain, neurological disorders, psychiatric disorders, and neuromuscular disorders. Compounds provided herein modulate the activity of opioid receptor (e.g., ?-opioid receptor) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: February 28, 2017
    Assignee: SUNOVION PHARMACEUTICALS, INC.
    Inventors: Scott Malcolm, Carrie Bowen, Laurence Melnick, Linghong Xie
  • Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
    Patent number: 9505751
    Abstract: Provided herein are substituted triazolopyrazine phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: November 29, 2016
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Phillip G. Jones, Scott Malcolm
  • Pyrrolidine triple reuptake inhibitors
    Patent number: 9505716
    Abstract: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: November 29, 2016
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Jianguo Ma
  • Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
    Patent number: 9498452
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: November 22, 2016
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
  • Acetamide stereoisomer
    Patent number: 9499476
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: November 22, 2016
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
  • Multicyclic compounds and methods of use thereof
    Patent number: 9351954
    Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. For example, disclosed herein are compounds having formula (IIa) shown below, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the variables are defined herein. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 31, 2016
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC.
    Inventors: Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
  • Metabotrophic glutamate receptor 5 modulators and methods of use thereof
    Patent number: 9260452
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 16, 2016
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors
    Patent number: 9249162
    Abstract: Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is ?wherein L, B and R3 are defined herein, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds and compositions provided herein are PDE-10 inhibitors and useful, e.g., for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: February 2, 2016
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Philip Jones, Michael Charles Hewitt
  • Triple reuptake inhibitors and methods of their use
    Patent number: 9133117
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: September 15, 2015
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Coated tablets of eszopiclone
    Patent number: 9114086
    Abstract: Coated tablets of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided. The tablets minimize the perceived bitterness of the medicament. A method for analyzing instantaneous dissolution of sub-microgram quantities of core material is also disclosed.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: August 25, 2015
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Richard Hsia, Cai Gu Huang, Konstantinos E. Saranteas, Tushar K. Misra, Philip J. Bonasia, Jr.